4FISH-IF, a Four-Color Dual-Gene FISH Combined with p63 Immunofluorescence to Evaluate NKX3.1 and MYC Status in Prostate Cancer

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 7, 2013, Pages 500-509

  Trudel, Dominique ^a,b   Zafarana, Gaetano ^a,c,d   Sykes, Jenna ^d   Have, Cherry L ^a   Bristow, Robert G ^c,d   van der Kwast, Theo ^a,d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

biopsy; fluorescence in situ hybridization; immunofluorescence; MYC; NKX3.1; prostate cancer

Indexed keywords

CELL MARKER; PROTEIN P63; CKAP4 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; MYC PROTEIN; MYC PROTEIN, HUMAN; NKX3 1 PROTEIN, HUMAN; NKX3-1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BASAL CELL; CENTROMERE; CHROMOSOME 8; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOFLUORESCENCE; MOLECULAR PATHOLOGY; MORPHOLOGY; ONCOGENE MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; TELOMERE; BIOPSY; COLOR; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; METHODOLOGY; MYC; NKX3.1; PATHOLOGY; PROSTATE TUMOR;

BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOFLUORESCENCE; MYC; NKX3.1; PROSTATE CANCER;

COLOR; FLUORESCENT ANTIBODY TECHNIQUE; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MEMBRANE PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS;

EID: 84882973285     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413490946     Document Type: Article

References (33)

1. Anderson PD,Mckissic SA,Logan M,Roh M,Franco OE,Wang J,Doubinskaia I,Van Der Meer R,Hayward SW,Eischen CM, et al.NKX3.1 and MYC crossregulate shared target genes in mouse and human prostate tumorigenesis.J Clin Invest. 2012;122:1907-1919.
2. Asatiani E,Huang WX,Wang A,Rodriguez Ortner E,Cavalli LR,Haddad BR,Gelmann EP.Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.Cancer Res. 2005;65:1164-1173.
3. Barry M,Perner S,Demichelis F,Rubin MA.TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.Urology. 2007;70:630-633.
4. Bethel CR,Faith D,Li X,Guan B,Hicks JL,Lan F,Jenkins RB,Bieberich CJ,De Marzo AM.Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion.Cancer Res. 2006;66:10683-10690.
5. Bowen C,Bubendorf L,Voeller HJ,Slack R,Willi N,Sauter G,Gasser TC,Koivisto P,Lack EE,Kononen J, et al.Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.Cancer Res. 2000;60:6111-6115.
6. Bowen C,Gelmann EP.NKX3.1 activates cellular response to DNA damage.Cancer Res. 2010;70:3089-3097.
7. Bowen C,Stuart A,Ju JH,Tuan J,Blonder J,Conrads TP,Veenstra TD,Gelmann EP.NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity.Cancer Res. 2007;67:455-464.
8. Brimo F,Epstein JI.Immunohistochemical pitfalls in prostate pathology.Hum Pathol. 2012;43:313-324.
9. Damber JE,Aus G.Prostate cancer.Lancet. 2008;371:1710-1721.
10. D'Amico AV,Whittington R,Malkowicz SB,Weinstein M,Tomaszewski JE,Schultz D,Rhude M,Rocha S,Wein A,Richie JP.Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.J Urol. 2001;166:2185-2188.
11. Epstein JI,Allsbrook WC,Amin MB,Egevad LL.The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma.Am J Surg Pathol. 2005;29:1228-1242.
12. Gurel B,Iwata T,Koh CM,Yegnasubramanian S,Nelson WG,De Marzo AM.Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.Adv Anat Pathol. 2008;15:319-331.
13. Ishkanian AS,Mallof CA,Ho J,Meng A,Albert M,Syed A,Van Der Kwast T,Milosevic M,Yoshimoto M,Squire JA, et al.High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer.Prostate. 2009;69:1091-1100.
14. Ishkanian AS,Zafarana G,Thoms J,Bristow RG.Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.Acta Oncol. 2010;49:888-894.
15. Iwata T,Schultz D,Hicks J,Hubbard GK,Mutton LN,Lotan TL,Bethel C,Lotz MT,Yegnasubramanian S,Nelson WG, et al.MYC overexpression induces prostatic intraepithelial neoplasia and loss of NKX3.1 in mouse luminal epithelial cells.Plos One. 2010;5:E9427.
16. Jemal A,Center MM,Ward E,Thun MJ.Cancer occurrence.Methods Mol Biol. 2009;471:3-29.
17. Kim JH,Dhanasekaran SM,Mehra R,Tomlins SA,Gu W,Yu J,Kumar-Sinha C,Cao X,Dash A,Wang L, et al.Integrative analysis of genomic aberrations associated with prostate cancer progression.Cancer Res. 2007;67:8229-8239.
18. Kindich R,Florl AR,Jung V,Engers R,Muller M,Schulz WA,Wullich B.Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer.Clin Chem. 2005;51:649-652.
19. Krenacs T,Krenacs L,Raffeld M.Multiple antigen immunostaining procedures.Methods Mol Biol. 2010;588:281-300.
20. Kron K,Liu L,Trudel D,Pethe V,Trachtenberg J,Fleshner NE,Bapat B,Van Der Kwast T.Correlation of erg expression and DNA methylation biomarkers with adverse clinicopathological features of prostate cancer.Clin Cancer Res. 2012;18:2896-2904.
21. Lapointe J,Li C,Giacomini CP,Salari K,Huang S,Wang P,Ferrari M,Hernandez-Boussard T,Brooks JD,Pollack JR.Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.Cancer Res. 2007;67:8504-8510.
22. Locke JA,Zafarana G,Ishkanian AS,Milosevic M,Thoms J,Have CL,Malloff CA,Lam WL,Squire JA,Pintilie M, et al.NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.Clin Cancer Res. 2012;18:308-316.
23. Mehra R,Han B,Tomlins SA,Wang L,Menon A,Wasco MJ,Shen R,Montie JE,Chinnaiyan AM,Shah RB.Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.Cancer Res. 2007;67:7991-7995.
24. Moore MW,Gasparini R.FISH as an effective diagnostic tool for the management of challenging melanocytic lesions.Diagn Pathol. 2011;6:76.
25. National Cancer Institute of Canada, Canadian Cancer Society, Provincial/Territorial Cancer Registries & Public Health Agency of Canada. 2011. Statistiques canadiennes sur le cancer. Toronto: Canadian Cancer Society.
26. Sato H,Minei S,Hachiya T,Yoshida T,Takimoto Y.Fluorescence in situ hybridization analysis of C_MYC amplification in stage TNM prostate cancer in Japanese patients.Int J Urol. 2006;13:761-766.
27. Sircar K,Yoshimoto M,Monzon FA,Koumakpayi IH,Katz RL,Khanna A,Alvarez K,Chen G,Darnel AD,Aprikian AG, et al.PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.J Pathol. 2009;218:505-513.
28. Speel EJ,Herbergs J,Ramaekers FC,Hopman AH.Combined immunocytochemistry and fluorescence in situ hybridization for simultaneous tricolor detection of cell cycle, genomic, and phenotypic parameters of tumor cells.J Histochem Cytochem. 1994;42:961-966.
29. Speel EJ,Schutte B,Wiegant J,Ramaekers FC,Hopman AH.A novel fluorescence detection method for in situ hybridization, based on the alkaline phosphatase-fast red reaction.J Histochem Cytochem. 1992;40:1299-1308.
30. van Duin M,Van Marion R,Vissers K,Watson JE,Van Weerden WM,Schroder FH,Hop WC,Van Der Kwast TH,Collins C,Van Dekken H.High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.Genes Chromosomes Cancer. 2005;44:438-449.
31. Wang X,Kruithof-De M,Economides KD,Walker D,Yu H,Halili MV,Hu YP,Price SM,Abate-Shen C,Shen MM.A luminal epithelial stem cell that is a cell of origin for prostate cancer.Nature. 2009;461:495-500.
32. Yang G,Timme TL,Frolov A,Wheeler TM,Thompson TC.Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.Cancer. 2005;103:1186-1194.
33. Zafarana G,Ishkanian AS,Malloff CA,Locke JA,Sykes J,Thoms J,Lam WL,Squire JA,Yoshimoto M,Ramnarine VR, et al.Copy number alterations of C-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.Cancer. 2012;118:4053-4062.